Publications by authors named "Daniel Forde Dilling"
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.
Suzana Margareth Lobo Gaétan Plantefève Girish Nair Adilson Joaquim Cavalcante Nara Franzin de Moraes Daniel Forde Dilling
EClinicalMedicine
February 2024
Article Synopsis
- The study examined whether Mas-receptor activation by BIO101 could help balance the Renin-Angiotensin System and reduce severe respiratory issues in hospitalized COVID-19 patients.
- It was a double-blind, randomized trial involving 238 participants, with findings showing a 11.4% lower rate of respiratory failure or early death in the BIO101 group compared to placebo.
- Results suggest BIO101 may reduce the risk of severe outcomes in COVID-19 patients, although further research is needed due to the low sample size.